| 杨宝刚,王庆凯,尹广利,马明静,杨 静,张成成.生脉注射液联合曲美他嗪治疗缺血性心肌病合并肾功能不全的临床疗效分析[J].,2019,19(5):942-945 |
| 生脉注射液联合曲美他嗪治疗缺血性心肌病合并肾功能不全的临床疗效分析 |
| Analysis of the Clinical Efficacy of Shengmai Injection plus Trimetazidine in the Treatment of Ischemic Cardiomyopathy Combined with Renal Insufficiency |
| 投稿时间：2018-10-08 修订日期：2018-10-31 |
| DOI：10.13241/j.cnki.pmb.2019.05.033 |
| 中文关键词: 生脉注射液 曲美他嗪 缺血性心肌病 肾功能不全 |
| 英文关键词: Shengmai injection Trimetazidine Ischemic cardiomyopathy Renal function protection Cystatin |
| 基金项目:河北省中医药管理局科研计划项目(2015288) |
|
| 摘要点击次数: 829 |
| 全文下载次数: 586 |
| 中文摘要: |
| 摘要 目的：研究生脉注射液联合曲美他嗪治疗缺血性心肌病合并肾功能不全的临床疗效。方法：选取2015年3月至2017年3月我院收治的100例缺血性心肌病合并肾功能不全患者，按照随机数表法分为观察组(n=50)和对照组(n=50)。对照组采用曲美他嗪治疗，观察组采用生脉注射液联合曲美他嗪治疗。观察和比较两组的治疗疗效、治疗前后心功能指标(左心室射血分数(LVEF)、左室收缩末径(LVESD)、左室舒张末期内径(LVEDD))、肾功能指标(血肌酐(Scr)，尿素氮(BUN))、心肌损伤标志物(血清胱抑素(CysC)、同型半胱氨酸(HCY)、脑钠肽(BNP))水平的变化。结果：治疗后，观察组总有效率显著高于对照组[92.30％(48/52) vs. 70.83％(34/48)] (P＜0.05)，LVEDD、LVESD水平均显著低于对照组［(51.21±8.54)mm vs. (56.63±10.83)mm，(42.91±6.30)mm vs. (45.86±7.32)mm］(P＜0.05)，LVEF水平均显著高于对照组［(46.02±7.85)％vs. (41.20±8.84)％］(P＜0.05)，Scr、BUN水平均显著低于对照组［(164.30±17.95)μmol/L vs. (211.75±19.31)μmol/L；(8.12±0.76)mmol/L vs. (11.74±1.72)mmol/L］(P＜0.05)。血清CysC、HCY、NT-ProBNP水平均显著低于对照组［(0.90±0.21)mg/L vs 1.52±0.34)mg/L(12.34±3.89)μmol/L vs. (20.86±5.28)μmol/L，(298.47±78.41)ng/L vs. (402.35±92.76)ng/L］(P＜0.05)。结论：生脉注射液联合曲美他嗪治疗缺血性心肌病合并肾功能不全的的临床疗效显著优于单用曲美他嗪治疗，其可有效改善患者心、肾功能，减轻心肌细胞损伤。 |
| 英文摘要: |
| ABSTRACT Objective: To study the clinical efficacy of shengmai injection plus trimetazidine in the treatment of ischemic car- diomyopathy combined with renal insufficiency. Methods: 100 cases of patients with ischemic cardiomyopathy and renal insufficiency who were treated from March 2015 to March 2017 in our hospital were selected as research objects. According to the random number table, those patients were divided into the observation group(n=50) and the control group(n=50). The control group was treated by trimetazidine, while the observation group treated by Shengmai injection combined with trimetazidine. Then the therapeutic efficacy, changes of left ventricular ejection fraction (LVEF), left ventricular end systolic diameter (LVESD), left ventricular end diastolic diameter (LVEDD), renal function index (Scr), urea nitrogen (BUN), myocardial injury markers (CysC), homocysteine (HCY), brain natriuretic peptide (BNP) levels were detected and compared between two groups before and after treatment. Results: After treatment, the total ef- fective rate of observation group was significantly higher than that of the control group[92.30％(48/52) vs. 70.83％(34/48)](P＜0.05). The levels of LVEDD and LVESD were significantly lower than those of the control group［(51.21±8.54)mm vs. (56.63±10.83)mm, (42.91±6.30)mm vs. (45.86±7.32)mm］(P＜0.05). The level of LVEF was significantly higher than that of control group［(46.02±7.85)％ vs. (41.20±8.84)％］(P＜0.05). The Scr and BUN levels were significantly lower than those in the control group［(164.30±17.95)μmol/L vs. (211.75±19.31)μmol/L; (8.12±0.76)mmol/L vs. (11.74±1.72)mmol/L］(P＜0.05). The serum CysC, HCY and NT-ProBNP levels were significantly lower than those in the control group［(0.90±0.21)mg/L vs. (1.52±0.34)mg/L(12.34±3.89)μmol/L vs. (20.86±5.28)μmol/L，(298.47±78.41)ng/L vs. (402.35±92.76)ng/L］(P＜0.05). Conclusion: The clinical efficacy of Sheng- mai injection combined with trimetazidine is significantly better than that of trimetazidine alone in the treatment of ischemic cardiomy- opathy with renal insufficiency. It can effectively improve the heart and kidney function of patients and reduce the damage of myocardial cells. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
